Safety, tolerability and gut microbIota AnalysiS of an Oral microbiotherapy in amyotrophic lateral sclerosis; an open-label phase 1b pilot trial

Previous Post

May 29, 2024: MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting